29.66
0.06 (0.20%)
| Previous Close | 29.60 |
| Open | 29.71 |
| Volume | 2,791,119 |
| Avg. Volume (3M) | 2,304,218 |
| Market Cap | 4,897,384,960 |
| Price / Earnings (TTM) | 14.76 |
| Price / Earnings (Forward) | 21.55 |
| Price / Sales | 3.74 |
| Price / Book | 3.22 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 23.30% |
| Operating Margin (TTM) | 4.50% |
| Diluted EPS (TTM) | 2.10 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Quarterly Earnings Growth (YOY) | -39.00% |
| Total Debt/Equity (MRQ) | 4.90% |
| Current Ratio (MRQ) | 3.33 |
| Operating Cash Flow (TTM) | 516.83 M |
| Levered Free Cash Flow (TTM) | 429.53 M |
| Return on Assets (TTM) | 11.62% |
| Return on Equity (TTM) | 25.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Alkermes plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.75 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.49% |
| % Held by Institutions | 107.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (Truist Securities, 85.44%) | Buy |
| Median | 45.00 (51.72%) | |
| Low | 37.00 (Wells Fargo, 24.75%) | Buy |
| Average | 45.20 (52.39%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 30.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 17 Nov 2025 | 55.00 (85.43%) | Buy | 29.33 |
| 12 Nov 2025 | 50.00 (68.58%) | Buy | 31.41 | |
| Deutsche Bank | 13 Nov 2025 | 45.00 (51.72%) | Buy | 31.01 |
| Wells Fargo | 13 Nov 2025 | 37.00 (24.75%) | Buy | 31.01 |
| 29 Oct 2025 | 42.00 (41.60%) | Buy | 31.45 | |
| Needham | 29 Oct 2025 | 44.00 (48.35%) | Buy | 31.45 |
| Mizuho | 27 Oct 2025 | 45.00 (51.72%) | Buy | 29.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 |
| 30 Dec 2025 | Announcement | Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2025 | Announcement | Alkermes to Participate in Two Upcoming Investor Conferences |
| 19 Nov 2025 | Announcement | Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc |
| 14 Nov 2025 | Announcement | Alkermes Response to Avadel Announcement |
| 12 Nov 2025 | Announcement | Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 |
| 06 Nov 2025 | Announcement | Alkermes to Participate in Two Upcoming Investor Conferences |
| 05 Nov 2025 | Announcement | FORM 8.1(a) & (b) (Opening Position Disclosure) |
| 28 Oct 2025 | Announcement | Alkermes plc Reports Third Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |